IP Library Granted Patent US 10,620,203
Granted Patent B2
US 10,620,203 · App. 14/679,430 · Granted Apr 14, 2020

Microfluidic device and leucocyte antigen mediated microfluidic assay

Inventors: Rodolfo R. Rodriguez (Cary, NC); Douglas J. Darr (Timberlake, NC)
Assignee: Advanced Animal Diagnostics, Inc.
G01N33/56972B01L3/5027C12M23/16C12M23/28C12M29/00G01N33/5091B01L3/50273B01L2300/0816B01L2300/0867B01L2400/0406G01N2015/008G01N2333/8107
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,620,203
App. No.
14/679,430
Granted
Apr 14, 2020
Kind
B2
Abstract

The present invention relates to an leucocyte antigen mediated microfluidic assay and a microfluidic device for analyzing a subjects' body fluids containing leucocytes to determine if the subject has been previously exposed to a predetermined antigen.

Claims (29)

1. A leucocyte antigen mediated microfluidic assay method for testing a leucocyte-containing body fluid from a subject for prior exposure to a predetermined antigen which would have caused leucocytes comprising one or more types of leucocytes to become presensitized to the antigen comprising:

performing a first test comprising the steps of:

a) placing a microvolume first sample of the subject's leucocyte-containing body fluid in a first sample microchamber;

b) transporting the first sample to a first reaction microchamber containing a predetermined antigen/antigen accelerator complex including the predetermined antigen and allowing the predetermined antigen/antigen accelerator complex and the first sample to react together for a predetermined time, wherein the antigen accelerator of the antigen/antigen accelerator complex is a composition that stimulates, amplifies and/or accelerates a production of measurement factors in leucocytes upon contact with the antigen of the antigen/antigen accelerator complex;

c) transporting the reacted first sample to a first observation microchamber;

d) mixing one or more leucocyte observation colorants with the reacted first sample, wherein mixing occurs either during transportation to the observation microchamber or in the observation microchamber;

e) optically performing a first optical scan of the reacted sample in the first observation microchamber, the first optical scan comprising a field-by-field XYZ scan under conditions which allow the measurement of at least one measurement factor of the leucocytes in the reacted first sample;

performing a second test comprising the steps of:

a) placing a microvolume second sample of the subject's leucocyte-containing body fluid in a second sample microchamber;

b) transporting the second sample to an antigen-free second reaction microchamber containing the same antigen accelerator of the antigen/antigen accelerator complex as the first test but not containing the antigen and allowing the second sample and the antigen accelerator to react for the predetermined time;

c) transporting the second sample to a second observation microchamber;

d) mixing the same leucocyte observation colorants as the first test with the reacted second sample, wherein mixing occurs either during transportation to the second observation microchamber or in the second observation microchamber;

e) optically performing a second optical scan of the reacted second sample in the second observation microchamber, the second optical scan comprising a field-by-field XYZ scan under conditions that allow the measurement of the same at least one leucocyte measurement factor measured in the first test;

comparing the results of the first optical scan to the second optical scan to determine if any differences between the first and second optical scans are due to a leucocyte-antigen mediated response, wherein the antigen accelerator of the antigen/antigen accelerator complex is α2-macroglobulin.

2. An assay method of claim 1 wherein the leucocytes comprise one or more of T-lymphocytes or neutrophils.

3. An assay method according to claim 1 wherein transportation is accomplished by capillary action.

4. An assay method of claim 1 wherein the first and second optical scans are accomplished by multi-wavelength fluorescence image analysis.

5. An assay method of claim 1 wherein the entire method is performed on a single disposable device.

6. An assay method of claim 1 wherein the measurement factors that are measured are morphological factors, spectral factors or both.

7. An assay method of claim 1 wherein a plurality of predetermined antigens are placed in the first reaction microchamber.

8. An assay method of claim 1 further comprising determining a quantitative antigen leucocyte reactivity by either measuring the number, relative intensity or both of the subject's reactive leucocytes while comparing the results of the first optical scan to the second.

9. An assay method of claim 1 , further comprising determining a measurement factor of the leucocytes, the measurement factor of the leucocytes comprises a leucocyte morphology and comparing the results of the first optical scan to the second optical scan to determine if any differences between the two scans are due to a leucocyte-antigen mediated response comprises determining a difference in the leucocyte morphology of the leucocytes in the first optical scan and the second optical scan.

10. An assay method of claim 1 , wherein the leucocyte-containing body fluid comprises whole blood and/or anticoagulated whole blood.

11. An assay method of claim 1 , wherein the leucocyte-containing body fluid comprises milk.

12. An assay method of claim 1 , wherein the leucocytes comprise neutrophils and lymphocytes and the step of comparing the results of the first optical scan to the second optical scan comprises comparing the results of the first optical scan to the second optical scan to determine if any differences between the two scans are due to a neutrophil-antigen mediated response or lymphocyte-antigen mediated response.

13. An assay method of claim 1 , wherein the leucocytes are T lymphocytes or neutrophils;

the first and second optical scans are accomplished by multi-wavelength fluorescence image analysis; the entire method is performed on a single disposable device; the measurement factors that are measured are morphological factors, spectral factors or both; and

a reaction of leucocytes with the antigen is determined by either measuring the number, relative intensity or both of the subject's reactive leucocytes while comparing the results of the first optical scan to the second optical scan.

14. An assay method of claim 1 , wherein the first and second observation microchambers have a wedge shape tapering from a widest point where fluid enters the first and second observation microchambers to an opposite end having a thickness of about 3 microns.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Oct 23, 2018
From: SILICON VALLEY BANK
To: ADVANCED ANIMAL DIAGNOSTICS, INC.
Reel/Frame 047276/0944 →
SECURITY INTEREST Recorded May 2, 2017
From: ADVANCED ANIMAL DIAGNOSTICS, INC.
To: CULTIVIAN SANDBOX FOOD & AGRICULTURE FUND II, L.P.; INTERSOUTH PARTNERS VII, L.P.; SANDBOX ADVANTAGE FUND, L.P.; ORIGAMI CAPITAL PARTNERS, LLC; MIDDLELAND AG FUND II, L.P.
Reel/Frame 042204/0515 →
SECURITY INTEREST Recorded Apr 3, 2017
From: ADVANCED ANIMAL DIAGNOSTICS, INC.
To: CULTIVIAN SANDBOX FOOD & AGRICULTURE FUND II, L.P.; INTERSOUTH PARTNERS VII, L.P.; SANDBOX ADVANTAGE FUND, L.P.; ORIGAMI CAPITAL PARTNERS, LLC; HANNAN, JTWROS, KAREN LEE AND ROBERT E.; GREENBAUM, GARY R.
Reel/Frame 041834/0684 →
SECURITY INTEREST Recorded Oct 20, 2016
From: ADVANCED ANIMAL DIAGNOSTICS, INC.
To: SILICON VALLEY BANK
Reel/Frame 040074/0453 →
SECURITY INTEREST Recorded Oct 20, 2016
From: ADVANCED ANIMAL DIAGNOSTICS, INC.
To: INTERSOUTH PARTNERS VII, L.P.; CULTIVAN SANDBOX FOOD & AGRICULTURE FUND II, L.P.; SANDBOX ADVANTAGE FUND, L.P.; LABORATORY CORPORATION OF AMERICA HOLDINGS
Reel/Frame 040079/0926 →
Continuity (3)
Continuation 11568832
Provisional Application 60570543 · May 13, 2004
Related Publication 20150275163A1 · Oct 1, 2015